A new analysis from the QUASAR study reveals that patients with ulcerative colitis (UC) who had previously shown intolerance or had failed to respond to advanced therapies still benefited from guselkumab treatment. The intravenous (IV) guselkumab 200 mg treatment for moderately to severely active UC resulted in significant improvements in clinical, symptomatic, and endoscopic outcomes compared to a placebo. While the most notable benefits were observed in patients without a history of intolerance to advanced therapies, the data suggests that prior intolerance to treatments like tumor necrosis factor (TNF) antagonists or Janus kinase (JAK) inhibitors shouldn’t prevent the use of guselkumab for UC patients. This information was presented at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, BC. The study, led by Dr. Brian Bressler, aimed to evaluate the efficacy of guselkumab versus placebo based on individual patient histories related to their response or intolerance to advanced therapy.